Yoram Drucker is an experienced biotechnology entrepreneur and executive with a diverse background in the development of innovative medical therapies. As a co-founder and board member of NurExone Biologic, Yoram Drucker focuses on revolutionary treatments for spinal cord injury and traumatic brain injury through siRNA-PTEN loaded exosome administration. Previous roles include board member and VP of business development at IR-Med Inc., which specializes in non-invasive spectrographic analysis, and founder of InnoCan Pharma, known for cannabinoid-based therapeutics. Yoram Drucker also co-founded and led ViruCure Therapeutics as CEO, working on oncolytic-virus-based cancer treatments, and held leadership positions at Cell Source Ltd., Rainbow Energy, Brainstorm Cell Therapeutics, and Pluristem Therapeutics, contributing to advancements in cell therapies and renewable energy solutions.
This person is not in any teams
This person is not in any offices
NurExone Biologic (OTCQB:NRXBF) (TSXV: NRX) (FSE: J90)
NurExone Biologic is developing a revolutionary biological exosome based technology drug platform to treat damage in the Central Nerve System. The breakthrough exosome-based technology was proven in preclinical studies to have the potential to treat spinal cord injuries.